Human monoclonal antibodies for discovery, therapy, and vaccine acceleration

Emanuele Andreano; Anja Seubert; Rino Rappuoli

doi:10.1016/j.coi.2019.07.005

Human monoclonal antibodies for discovery, therapy, and vaccine acceleration

Curr Opin Immunol. 2019 Aug:59:130-134. doi: 10.1016/j.coi.2019.07.005. Epub 2019 Aug 23.

Authors

Emanuele Andreano¹, Anja Seubert², Rino Rappuoli³

Affiliations

¹ vAMRes Lab, Toscana Life Sciences, Siena, Italy.
² GSK, Siena, Italy.
³ vAMRes Lab, Toscana Life Sciences, Siena, Italy; GSK, Siena, Italy; Imperial College, London, United Kingdom. Electronic address: [email protected].

PMID: 31450054
DOI: 10.1016/j.coi.2019.07.005

Abstract

Screening of single B cells from convalescent or vaccinated people allows the discovery of novel targets for infectious diseases and rapid production of engineered human monoclonal antibodies (mAbs) that can prevent or control infections by passive immunization. Here we propose that the development of human mAbs can also significantly accelerate vaccine development by anticipating some of the key biological and regulatory questions.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antibodies, Monoclonal / immunology*
Antibodies, Monoclonal / therapeutic use
Antibodies, Neutralizing / metabolism
Antibodies, Viral / metabolism
Antineoplastic Agents, Immunological / therapeutic use*
B-Lymphocytes / physiology*
Bioengineering
Communicable Disease Control
Humans
Immunotherapy / methods*
Neoplasms / immunology
Neoplasms / therapy*
Single-Cell Analysis
Vaccines / immunology*
Virus Diseases / immunology*

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Antineoplastic Agents, Immunological
Vaccines